Teva's new migraine treatment drug Fremanezumab is released in Korea. It was approved by the U.S. Food and Drug Administration (FDA) in May 2018 in the calcitonin gene-released peptide (CGRP) family.

The MFDS approved two items of Handok Teva's migraine prevention drug Ajovy on Wednesday. Two formulations of Ajovy Prefilled Syringe and Ajovy Auto Injector have been approved.

These drugs can be used to prevent migraines in adults, and subcutaneous injections can be made every 1 month or 3 months. It is a CGRP-based antibody treatment drug such as Emgality which was approved by the MFDS in September 2019.

Clinical trials of Fremanezumab was conducted to confirm the effect o